Research programme: rituximab biosimilar - Coherus BioSciences/Daiichi Sankyo

Drug Profile

Research programme: rituximab biosimilar - Coherus BioSciences/Daiichi Sankyo

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus Biosciences; Daiichi Sankyo Company
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Follicular lymphoma; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Follicular lymphoma in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Microscopic polyangiitis in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top